Fig. 6From: Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndromePlasma HMGB1 levels in the four MAS patients before and after etoposide therapy. Plasma HMGB1 measured by ELISA was markedly increased in all patients during severe MAS before etoposide (Eto) treatment was added to ongoing therapy. Plasma HMGB1 concentration immediately before first dose of etoposide was compared to last available sample. HMGB1 levels were significantly reduced (*p < 0.05) post etoposide administrationBack to article page